Following the Court Ordered Meeting held on December 5, 2023 – at which the shareholders of GlaxoSmithKline Consumer Nigeria Plc approved the proposed Scheme of Arrangement, the Company has notified Nigerian Exchange Limited, shareholders and other stakeholders that the Company has now received Securities and Exchange Commission’s Formal Approval of the Scheme.
The order of the Federal High Court sanctioning the Scheme of Arrangement has also been obtained.
An application for the delisting of the Company’s shares from the NGX will be submitted imminently.